Study of Salirasib to Treat Non-Small Cell Lung Cancer

NCT00531401 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Salirasib

Sponsor

Concordia Pharmaceuticals, Inc